News from newlink genetics corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 03, 2013, 07:30 ET

NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting

 NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced...

Jun 03, 2013, 07:30 ET

NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer

NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results...

Jun 01, 2013, 09:00 ET

NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting

 NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced...

May 29, 2013, 08:00 ET

NewLink Genetics to Present at the Jefferies 2013 Healthcare Conference

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel...

Apr 25, 2013, 07:00 ET

NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing...

Apr 08, 2013, 07:00 ET

NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting

NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing...

Apr 04, 2013, 07:00 ET

NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer

 NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing cancer...

Apr 02, 2013, 07:00 ET

NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...

Feb 25, 2013, 11:54 ET

NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call

 NewLink Genetics Corporation (Nasdaq:NLNK) today announced that its Fourth Quarter and fiscal year ended December 31, 2012 financial results...

Feb 04, 2013, 09:57 ET

NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...

Jan 30, 2013, 09:08 ET

NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...

Jan 29, 2013, 16:16 ET

NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...

Jan 03, 2013, 07:00 ET

NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel...

Dec 13, 2012, 07:00 ET

Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy

 NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a  Phase 1 dose escalation study with its proprietary...

Nov 14, 2012, 07:00 ET

NewLink Genetics Receives European Orphan Designation for Algenpantucel-L Immunotherapy to Treat Pancreatic Cancer

 NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the European Commission (EC) has designated HyperAcute-Pancreas®...

Nov 07, 2012, 07:00 ET

Lota S. Zoth joins NewLink's Board of Directors; heads Audit Committee

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...

Oct 10, 2012, 06:00 ET

NewLink Genetics Launches Phase 3 Clinical Trial of algenpantucel-L Immunotherapy in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

 NewLink Genetics Corporation (Nasdaq: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients...

Oct 03, 2012, 07:53 ET

NewLink Genetics Launches Adaptive Design Phase 2B/3 Clinical Trial of tergenpumatucel-L Immunotherapy in Patients with Non-Small Cell Lung Cancer

 NewLink Genetics Corporation (Nasdaq: NLNK) announces the launching of an open-label, randomized, multi-institutional adaptive design...

Oct 02, 2012, 07:00 ET

NewLink to Present at 3rd Annual Cancer Immunotherapy Conference

 NewLink Genetics (NASDAQ:NLNK) today announced that the company will be presenting at the 3rd Annual Cancer Immunotherapy: A Long-Awaited...

Jan 21, 2011, 08:00 ET

NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute®...